cmv/ebv specific t-cell
Cell therapyexperimental
Clinical trial activity
2 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02227641)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human herpesvirus 4Immunity, active
Human herpesvirus 4 immunity, active
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cmv/ebv specific t-cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02456610 | Phase 1 | May 1, 2015 | People's Liberation Army of China |
| NCT02227641 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2014 | BayImmuNet Bavarian Immunotherapy Network, German Research Foundation, Humboldt University, Johannes Gutenburg University, Ludwig Maximilians University, University of Erlangen-Nuremberg, University of Regensburg |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BayImmuNet Bavarian Immunotherapy Network | Academic/Hospital | 1 | 0 | 1 | 2014 |
| German Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Ludwig Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2015 |
| University of Erlangen-Nuremberg | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Regensburg | Academic/Hospital | 1 | 0 | 1 | 2014 |
8 organizations
Page 1 / 1